WallStreetZenWallStreetZen

NYSE: WST
West Pharmaceutical Services Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for WST

Based on 4 analysts offering 12 month price targets for West Pharmaceutical Services Inc

Min Forecast
$320.00-12.33%
Avg Forecast
$351.25-3.77%
Max Forecast
$400.00+9.59%

Should I buy or sell WST stock?

Based on 4 analysts offering ratings for West Pharmaceutical Services Inc.

Strong Buy
Strong Buy
2 analysts 50%
Buy
1 analysts 25%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their WST stock forecasts and price targets.

WST stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-09
lockedlocked$00.00+00.00%2026-06-02
lockedlocked$00.00+00.00%2026-05-29
lockedlocked$00.00+00.00%2026-02-03

1 of 1

Forecast return on equity

Is WST forecast to generate an efficient return?

Company
26.32%
Industry
24.67%
Market
172.55%
WST's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is WST forecast to generate an efficient return on assets?

Company
19.15%
Industry
18.13%
WST is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

WST earnings per share forecast

What is WST's earnings per share in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
$8.70+15.63%
Avg 2 year Forecast
$9.63+28.1%
Avg 3 year Forecast
$10.81+43.71%
WST's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

WST revenue forecast

What is WST's revenue in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
$3.4B+4.47%
Avg 2 year Forecast
$3.6B+10.87%
Avg 3 year Forecast
$3.8B+18.66%
WST's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

WST earnings growth forecast

How is WST forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
12.66%
Industry
28.05%
Market
34.16%
WST's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
WST's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
WST's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

WST revenue growth forecast

How is WST forecast to perform vs Medical Instruments & Supplies companies and vs the US market?

Company
5.77%
Industry
9.36%
Market
14.13%
WST's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
WST's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

WST vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
WST$365.00$351.25-3.77%Strong Buy
RMD$201.10$268.00+33.27%Buy
ALC$66.82$85.43+27.85%Buy
COO$71.95$82.80+15.08%Buy
BAX$21.69$20.75-4.33%Hold
View Top Medical Stocks

West Pharmaceutical Services Stock Forecast FAQ

Is West Pharmaceutical Services Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NYSE: WST) stock is to Strong Buy WST stock.

Out of 4 analysts, 2 (50%) are recommending WST as a Strong Buy, 1 (25%) are recommending WST as a Buy, 1 (25%) are recommending WST as a Hold, 0 (0%) are recommending WST as a Sell, and 0 (0%) are recommending WST as a Strong Sell.

If you're new to stock investing, here's how to buy West Pharmaceutical Services stock.

What is WST's earnings growth forecast for 2026-2028?

(NYSE: WST) West Pharmaceutical Services's forecast annual earnings growth rate of 12.66% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 28.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.16%.

West Pharmaceutical Services's earnings in 2026 is $542,700,000.On average, 18 Wall Street analysts forecast WST's earnings for 2026 to be $614,316,162, with the lowest WST earnings forecast at $586,417,427, and the highest WST earnings forecast at $654,267,377. On average, 17 Wall Street analysts forecast WST's earnings for 2027 to be $680,569,477, with the lowest WST earnings forecast at $627,958,213, and the highest WST earnings forecast at $762,344,068.

In 2028, WST is forecast to generate $763,467,365 in earnings, with the lowest earnings forecast at $690,961,738 and the highest earnings forecast at $859,152,468.

What is WST's revenue growth forecast for 2026-2028?

(NYSE: WST) West Pharmaceutical Services's forecast annual revenue growth rate of 5.77% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.

West Pharmaceutical Services's revenue in 2026 is $3,221,000,000.On average, 18 Wall Street analysts forecast WST's revenue for 2026 to be $237,729,157,175, with the lowest WST revenue forecast at $228,686,265,015, and the highest WST revenue forecast at $252,565,152,125. On average, 18 Wall Street analysts forecast WST's revenue for 2027 to be $252,282,561,745, with the lowest WST revenue forecast at $238,788,871,100, and the highest WST revenue forecast at $270,580,288,850.

In 2028, WST is forecast to generate $270,015,108,090 in revenue, with the lowest revenue forecast at $253,978,104,025 and the highest revenue forecast at $290,644,205,830.

What is WST's forecast return on assets (ROA) for 2026-2029?

(NYSE: WST) forecast ROA is 19.15%, which is higher than the forecast US Medical Instruments & Supplies industry average of 18.13%.

What is WST's Price Target?

According to 4 Wall Street analysts that have issued a 1 year WST price target, the average WST price target is $351.25, with the highest WST stock price forecast at $400.00 and the lowest WST stock price forecast at $320.00.

On average, Wall Street analysts predict that West Pharmaceutical Services's share price could fall to $351.25 by Jun 9, 2027. The average West Pharmaceutical Services stock price prediction forecasts a potential downside of 3.77% from the current WST share price of $365.00.

What is WST's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: WST) West Pharmaceutical Services's current Earnings Per Share (EPS) is $7.52. On average, analysts forecast that WST's EPS will be $8.70 for 2026, with the lowest EPS forecast at $8.30, and the highest EPS forecast at $9.26. On average, analysts forecast that WST's EPS will be $9.63 for 2027, with the lowest EPS forecast at $8.89, and the highest EPS forecast at $10.79. In 2028, WST's EPS is forecast to hit $10.81 (min: $9.78, max: $12.16).

What is WST's forecast return on equity (ROE) for 2026-2029?

(NYSE: WST) forecast ROE is 26.32%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.